Since E3L.CETP mice are a well-established model for human-like lipoprotein metabolism and atherosclerosis development, we anticipate that even in the absence of obesity, CB1R antagonism may be a promising strategy to combat CVD, probably through lowering lipids as well as inflammation. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.